---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056935"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T07:08:50.476664+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences Q1 net loss $18.2M; cash $382.5M; TYRA-300 on track for 2H24 milestones

## Summary
- Net loss of $18.2M in Q1 2024 vs $11.9M in Q1 2023; R&D expenses $17.2M.
- Cash, equivalents, and marketable securities of $382.5M as of March 31, 2024; funding through at least 2026.
- Closed $200M private placement in Feb 2024.
- TYRA-300 on track for ACH IND submission and initial SURF301 results in 2H24.
- Appointed Susan Moran, M.D. and S. Michael Rothenberg, M.D., Ph.D. to board.

## SEC filing metadata
- accession: 0000950170-24-056935
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000095017024056935/0000950170-24-056935-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000095017024056935/tyra-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056935
- JSON: https://secwatch.observer/filing/0000950170-24-056935.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056935.txt

## Key facts
- Earnings Releases
  Tyra Biosciences, Inc. reported the quarter ended March 31, 2024 results: net income First quarter 2024 net loss was $18.2 million.
  - Period: the quarter ended March 31, 2024
  - Net income: First quarter 2024 net loss was $18.2 million
  - Result: reported results
  source text: On May 9, 2024, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1863127/000095017024056935/0000950170-24-056935-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.